312 related articles for article (PubMed ID: 30737829)
21. Abuse liability of gabapentin in the Saudi population after the pregabalin restriction: A cross-sectional study.
Alkhalaf AA; Bukhari RA; Alshehri EA; Alshehri SO; Badr AF
J Taibah Univ Med Sci; 2021 Oct; 16(5):700-705. PubMed ID: 34690650
[TBL] [Abstract][Full Text] [Related]
22. Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability.
Evoy KE; Peckham AM; Covvey JR; Tidgewell KJ
J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S89-S99. PubMed ID: 34396549
[TBL] [Abstract][Full Text] [Related]
23. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
24. Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample.
Evoy KE; Covvey JR; Peckham AM; Reveles KR
Int J Clin Pharm; 2021 Aug; 43(4):1055-1064. PubMed ID: 33387188
[TBL] [Abstract][Full Text] [Related]
25. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden.
Molero Y; Larsson H; D'Onofrio BM; Sharp DJ; Fazel S
BMJ; 2019 Jun; 365():l2147. PubMed ID: 31189556
[TBL] [Abstract][Full Text] [Related]
26. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
[TBL] [Abstract][Full Text] [Related]
27. Pregabalin misuse in methadone maintenance treatment patients in Israel: Prevalence and risk factors.
Sason A; Adelson M; Schreiber S; Peles E
Drug Alcohol Depend; 2018 Aug; 189():8-11. PubMed ID: 29857329
[TBL] [Abstract][Full Text] [Related]
28. Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial.
Robertson K; Marshman LAG; Plummer D; Downs E
JAMA Neurol; 2019 Jan; 76(1):28-34. PubMed ID: 30326006
[TBL] [Abstract][Full Text] [Related]
29. An algorithm to identify gabapentin misuse and/or abuse in administrative claims data.
Zhao D; Nunes AP; Baek J; Lapane KL
Drug Alcohol Depend; 2022 Jun; 235():109429. PubMed ID: 35427982
[TBL] [Abstract][Full Text] [Related]
30. Use of Pregabalin - A Nationwide Pharmacoepidemiological Drug Utilization Study with Focus on Abuse Potential.
Schjerning O; Pottegård A; Damkier P; Rosenzweig M; Nielsen J
Pharmacopsychiatry; 2016 Jul; 49(4):155-61. PubMed ID: 26951495
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with pregabalin dispensing at higher than the approved maximum dose.
Bodén R; Wettermark B; Brandt L; Kieler H
Eur J Clin Pharmacol; 2014 Feb; 70(2):197-204. PubMed ID: 24141597
[TBL] [Abstract][Full Text] [Related]
32. The risk of fragility fractures following initiation of gabapentin and pregabalin-A Danish, nationwide, high-dimensional propensity score-matched cohort study.
Jørgensen EB; Overgaard LK; Folkestad L; Damkier P; Hallas J; Henriksen DP
Basic Clin Pharmacol Toxicol; 2023 May; 132(5):384-391. PubMed ID: 36526604
[TBL] [Abstract][Full Text] [Related]
33. Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc Analysis.
Tanenberg RJ; Clemow DB; Giaconia JM; Risser RC
Pain Pract; 2014 Sep; 14(7):640-8. PubMed ID: 24152185
[TBL] [Abstract][Full Text] [Related]
34. French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol.
Gérardin M; Rousselet M; Caillet P; Grall-Bronnec M; Loué P; Jolliet P; Victorri-Vigneau C
BMJ Open; 2019 Jun; 9(6):e027443. PubMed ID: 31256026
[TBL] [Abstract][Full Text] [Related]
35. Incidence of tramadol shopping behavior in a retrospective cohort of chronic non-cancer pain patients in France.
Chenaf C; Kabore JL; Delorme J; Pereira B; Mulliez A; Roche L; Eschalier A; Delage N; Authier N
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1088-98. PubMed ID: 27363310
[TBL] [Abstract][Full Text] [Related]
36. How addictive are gabapentin and pregabalin? A systematic review.
Bonnet U; Scherbaum N
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1185-1215. PubMed ID: 28988943
[TBL] [Abstract][Full Text] [Related]
37. Characterizing early prescribers of newly marketed drugs in Canada: a population-based study.
Kozyrskyj A; Raymond C; Racher A
Eur J Clin Pharmacol; 2007 Jun; 63(6):597-604. PubMed ID: 17380324
[TBL] [Abstract][Full Text] [Related]
38. Patterns of pregabalin prescribing in four German federal states: analysis of routine data to investigate potential misuse of pregabalin.
Flemming R
BMJ Open; 2022 Jul; 12(7):e060104. PubMed ID: 35879005
[TBL] [Abstract][Full Text] [Related]
39. Racial-Ethnic Disparities in Opioid Prescriptions at Emergency Department Visits for Conditions Commonly Associated with Prescription Drug Abuse.
Singhal A; Tien YY; Hsia RY
PLoS One; 2016; 11(8):e0159224. PubMed ID: 27501459
[TBL] [Abstract][Full Text] [Related]
40. Gabapentin and Pregabalin Use and Association with Adverse Outcomes among Hemodialysis Patients.
Ishida JH; McCulloch CE; Steinman MA; Grimes BA; Johansen KL
J Am Soc Nephrol; 2018 Jul; 29(7):1970-1978. PubMed ID: 29871945
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
